Vol. 22/No. 22

Bintrafusp Alfa, a novel fusion protein designed to target the transforming growth factor beta pathway, racked up 3 clinical trial disappointments in less than a year, leaving the future of its development in question.

At the onset of the pandemic, hematology/oncology physicians were challenged in counseling patients with serious underlying malignant conditions about their risk for severe disease due to COVID-19.

Investigators hope to improve upon the efficacy and tolerability of androgens in the treatment of breast cancer with the October 13, 2021, initiation of the phase 3 ARTEST trial.

Jorge E. Cortes, MD, has been an investigative leader for nearly 30 years in the development of numerous leukemia treatments.

A panel of breast cancer experts shared their insights on 4 recently approved targeted therapies for patients with relapsed HER2-positive metastatic breast cancer.

Various immune strategies have been developed in multiple myeloma, including immune-enhancing drugs such as immunomodulatory drugs, checkpoint inhibitors, monoclonal antibodies, and, more recently, chimeric antigen receptor T-cell therapy and bispecific antibodies for T-cell redirection.

Bijal Shah, MD, MS, discussed the results of the ZUMA-3 trial and how this approval will enhance the treatment of patients with relapsed or refractory B-cell precursor ALL.

Nasser Khaled Altorki, MD, provides insight on the results of the IMpower010 trial as well as post hoc analyses from the trial and what they signal for the remainder of this patient population.

Maurie Markman, MD, discusses how agency leaders should be encouraged to improve regulatory science, include a patient’s perspective in approval decisions, reduce unnecessary bureaucracy and costs associated with the conduct of trials, and accelerate the overall review process for drug approval.